RxDoctor Payments Data

Michelle Butler, MD

Ophthalmology · Dallas, TXNPI 1447403837

Payments from drug & device makers

$52,756in general payments, 2019–2025

Across 165 payments — averaging $319.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$25K
  • AbbVie$20K
  • NEW World Medical,inc.$5K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Amgen$333
  • Alcon$313
  • plus $616 from 11 others

What the payments were for

  • Consulting fees$7,73066%
  • Speaking & faculty fees$4003%
  • Travel & lodging$971%
  • Food & beverage$3,44629%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,756 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$540,837
Medicare patients
1,065
Services billed
5,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate161$66,773
LumiganBimatoprost130$65,045
CombiganBrimonidine Tartrate/Timolol141$58,459
VyzultaLatanoprostene Bunod103$47,312
RocklatanNetarsudil Mesylat/Latanoprost76$43,787
RestasisCyclosporine33$38,605
Alphagan PBrimonidine Tartrate90$35,864
Prednisolone Acetate515$24,618
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol158$24,146
Brimonidine Tartrate691$23,778
Latanoprost2,357$22,800
SimbrinzaBrinzolamide/Brimonidine Tart70$21,164
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,242$20,274
Travoprost80$13,757
Dorzolamide-TimololDorzolamide/Timolol/Pf77$12,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$19,805$197,972394 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$259$110,560237 claims
Bausch & Lomb Americas Inc.Vyzulta$92$47,312103 claims
AlconSimbrinza$313$21,16470 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa$2,019$13,80347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →